Analysts See $0.25 EPS for Anika Therapeutics, Inc. (ANIK)

April 20, 2018 - By wolcottdaily

Anika Therapeutics, Inc. (NASDAQ:ANIK) LogoInvestors sentiment decreased to 1.37 in 2017 Q4. Its down 0.05, from 1.42 in 2017Q3. It is negative, as 12 investors sold Anika Therapeutics, Inc. shares while 45 reduced holdings. 24 funds opened positions while 54 raised stakes. 12.26 million shares or 0.18% less from 12.29 million shares in 2017Q3 were reported.
Us Bancorporation De holds 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 1,060 shares. Teachers Retirement Sys Of The State Of Kentucky has 0.02% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). Mcf Advisors Llc invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Gabelli Funds Ltd Limited Liability Company stated it has 7,000 shares. Moreover, Los Angeles Capital Mgmt Equity Research Inc has 0.01% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). The United Kingdom-based Barclays Pcl has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Ngam Advisors Limited Partnership reported 119,453 shares. Hl Svcs Llc stated it has 5,714 shares or 0.01% of all its holdings. Millennium Management Ltd Limited Liability Company reported 3,861 shares. Bnp Paribas Arbitrage holds 0% or 14,093 shares. Bogle Inv Mngmt L P De holds 5,200 shares. Hutchin Hill Ltd Partnership has 12,400 shares for 0.19% of their portfolio. Seaward Mngmt L P holds 0.08% or 32,300 shares. Tiaa Cref Investment Mgmt Limited Liability Co has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Morgan Stanley has invested 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK).

Since October 20, 2017, it had 0 insider buys, and 1 sale for $196,811 activity.

Analysts expect Anika Therapeutics, Inc. (NASDAQ:ANIK) to report $0.25 EPS on May, 2.They anticipate $0.12 EPS change or 32.43 % from last quarter’s $0.37 EPS. ANIK’s profit would be $3.69M giving it 45.64 P/E if the $0.25 EPS is correct. After having $0.38 EPS previously, Anika Therapeutics, Inc.’s analysts see -34.21 % EPS growth. The stock increased 0.24% or $0.11 during the last trading session, reaching $45.64. About 49,831 shares traded. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 15.35% since April 20, 2017 and is uptrending. It has outperformed by 3.80% the S&P500.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics Inc (NASDAQ:ANIK), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Anika Therapeutics Inc had 3 analyst reports since December 28, 2017 according to SRatingsIntel. First Analysis upgraded the stock to “Overweight” rating in Wednesday, January 24 report. The firm has “Market Perform” rating by Barrington Research given on Friday, February 23.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $672.97 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 21.63 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.